glp-1 agonists vs sglt2 inhibitors Efficacy and safety of LY3298176, a novel dual GIP and receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Tirzepatide, a dual GIP/GLP-1 receptor
Pay in 4 interest-free payments of $5.30 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19

























